Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NETWORK × darolutamide × Clear all

Phase

Phase 2 2 Phase 3 1

Status

Sponsor Class

OTHER 7 INDUSTRY 5 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Adenocarcinoma 1

Interventions

Radiotherapy 120 Cyclophosphamide 95 Cisplatin 93 Doxorubicin 86 Vincristine 67 Filgrastim 53 Etoposide 51 Paclitaxel 48 Carboplatin 47 Fluorouracil 45 Methotrexate 42 Dexamethasone 40 Prednisone 37 Cytarabine 36 Leucovorin 32 Granulocyte Colony-Stimulating Factor 30 Docetaxel 29 Radiation 27 Ifosfamide 24 Daunorubicin 23 Tamoxifen 21 Specimen Handling 21 Calcium Dobesilate 21 Platinum 20 Mercaptopurine 20 Gemcitabine 20 Chemotherapy, Adjuvant 20 1,2-diaminocyclohexaneplatinum II citrate 20 Magnetic Resonance Spectroscopy 18 Goserelin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06592924 2026-01-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡